Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C13H13N3O3.ClH.H2O |
| Molecular Weight | 313.737 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.Cl.NC1=CC=CC2=C1CN(C3CCC(=O)NC3=O)C2=O
InChI
InChIKey=NEUSAGZHGGOOIV-UHFFFAOYSA-N
InChI=1S/C13H13N3O3.ClH.H2O/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18;;/h1-3,10H,4-6,14H2,(H,15,17,18);1H;1H2
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22966948
http://www.revlimidrems.com/
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22966948
http://www.revlimidrems.com/
Lenalidomide (trade name Revlimid) is a derivative of thalidomide introduced in 2004. It is an immunomodulatory agent with anti-angiogenic properties. Revlimid in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM) who have received at least one prior therapy. Also is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. In addition, Revlimid is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. The mechanism of action of lenalidomide remains to be fully characterized. Lenalidomide inhibited the secretion of pro-inflammatory cytokines and increased the secretion of anti-inflammatory cytokines from peripheral blood mononuclear cells. Lenalidomide causes a delay in tumor growth in some in vivo nonclinical hematopoietic tumor models including multiple myeloma. Immunomodulatory properties of lenalidomide include activation of T cells and natural killer (NK) cells, increased numbers of NKT cells, and inhibition of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes. In multiple myeloma cells, the combination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis. Recently was discovered, that protein cereblon (CRBN) is a proximate, therapeutically important molecular target of lenalidomide. Low CRBN expression was found to correlate with drug resistance in multiple myeloma (MM) cell lines and primary MM cells. One of the downstream targets of CRBN identified is interferon regulatory factor 4 (IRF4), which is critical for myeloma cell survival and is down-regulated by (immune-modulatory drugs) treatment. CRBN is also implicated in several effects of immunomodulatory drugs, such as down-regulation of tumor necrosis factor-α (TNF-α) and T cell immunomodulatory activity, demonstrating that the pleotropic actions of the immunomodulatory drugs (IMiDs) are initiated by binding to CRBN. Future dissection of CRBN downstream signaling will help to delineate the underlying mechanisms for IMiD action and eventually lead to development of new drugs with more specific anti-myeloma activities. It may also provide a biomarker to predict IMiD response and resistance. Lenalidomide also inhibited the expression of cyclooxygenase-2 (COX-2) but not COX-1 in vitro.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Q96SW2 Gene ID: 51185.0 Gene Symbol: CRBN Target Organism: Homo sapiens (Human) |
3.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | REVLIMID Approved UseREVLIMID is a thalidomide analogue indicated for the treatment of patients with: Multiple myeloma (MM), in combination with dexamethasone (1.1). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities (1.2). Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib (1.3). Limitations of Use: REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials (1.4). 1.1 Multiple Myeloma REVLIMID in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM). 1.2 Myelodysplastic Syndromes REVLIMID is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. 1.3 Mantle Cell Lymphoma REVLIMID is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. 1.4 Limitations of Use: REVLIMID is not indicated and is not recommended for the treatment of patients with CLL outside of controlled clinical trials [see Warnings and Precautions (5.5) Launch Date2005 |
|||
| Primary | REVLIMID Approved UseREVLIMID is a thalidomide analogue indicated for the treatment of patients with: Multiple myeloma (MM), in combination with dexamethasone (1.1). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities (1.2). Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib (1.3). Limitations of Use: REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials (1.4). 1.1 Multiple Myeloma REVLIMID in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM). 1.2 Myelodysplastic Syndromes REVLIMID is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. 1.3 Mantle Cell Lymphoma REVLIMID is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. 1.4 Limitations of Use: REVLIMID is not indicated and is not recommended for the treatment of patients with CLL outside of controlled clinical trials [see Warnings and Precautions (5.5) Launch Date2005 |
|||
| Primary | REVLIMID Approved UseREVLIMID is a thalidomide analogue indicated for the treatment of patients with: Multiple myeloma (MM), in combination with dexamethasone (1.1). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities (1.2). Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib (1.3). Limitations of Use: REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials (1.4). 1.1 Multiple Myeloma REVLIMID in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM). 1.2 Myelodysplastic Syndromes REVLIMID is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. 1.3 Mantle Cell Lymphoma REVLIMID is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. 1.4 Limitations of Use: REVLIMID is not indicated and is not recommended for the treatment of patients with CLL outside of controlled clinical trials [see Warnings and Precautions (5.5) Launch Date2005 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
433.1 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29411269 |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
LENALIDOMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1252.08 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02538965 |
2 mg/kg single, oral dose: 2 mg/kg route of administration: oral experiment type: single co-administered: |
LENALIDOMIDE plasma | Homo sapiens population: unhealthy age: Children sex: food status: |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1472.4 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29411269 |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
LENALIDOMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5378.83 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02538965 |
2 mg/kg single, oral dose: 2 mg/kg route of administration: oral experiment type: single co-administered: |
LENALIDOMIDE plasma | Homo sapiens population: unhealthy age: Children sex: food status: |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29411269 |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
LENALIDOMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
70% |
LENALIDOMIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
25 mg 1 times / day multiple, oral Highest studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: |
unhealthy, 35 years (range: 20-70years) n = 3 Health Status: unhealthy Condition: Relapsed or Refractory Classical Hodgkin Lymphoma Age Group: 35 years (range: 20-70years) Sex: M+F Population Size: 3 Sources: |
|
10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
pregnant, adult Health Status: pregnant Age Group: adult Sex: F Sources: |
Other AEs: Birth defects... Other AEs: Birth defects (serious) Sources: |
10 mg 1 times / day steady, oral (starting) Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: Page: p. 101 |
unhealthy, adult n = 395 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 395 Sources: Page: p. 101 |
Disc. AE: Thrombocytopenia, Neutropenia... AEs leading to discontinuation/dose reduction: Thrombocytopenia (6.1%) Sources: Page: p. 101Neutropenia (3.5%) Rash (2%) Nausea (1.5%) Diarrhea (1.3%) Fatigue (1%) Anaemia NOS (1%) Abdominal distension (1%) Pyrexia (0.8%) Dyspnea (0.8%) Cough (0.5%) Abdominal pain NOS (0.5%) Face edema (0.5%) Pruritus (0.5%) Anemia hemolytic (NOS) (0.5%) Pneumonia NOS (1%) Arthralgia (0.5%) |
10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Neutropenia, Thrombocytopenia... Other AEs: Neutropenia Sources: Thrombocytopenia Thrombosis venous deep Pulmonary embolism |
10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 87 Health Status: unhealthy Condition: Complex Regional Pain Syndrome Population Size: 87 Sources: |
Other AEs: Joint sprain, Foot fracture... Other AEs: Joint sprain (serious, 2 patients) Sources: Foot fracture (serious, 1 patient) Thrombosis (serious, 1 patient) Blood human chorionic gonadotropin positive (serious, 1 patient) Blood potassium decreased (serious, 1 patient) Pregnancy test false positive (serious, 1 patient) Sick sinus syndrome (serious, 1 patient) Pregnancy NOS (serious, 2 patients) Abortion spontaneous NOS (serious, 1 patient) Pain NOS (serious, 1 patient) Arthritis NOS (serious, 1 patient) Angioneurotic edema (serious, 1 patient) Rash NOS (below serious, 24 patients) Pruritus (below serious, 8 patients) Dry skin (below serious, 6 patients) Diarrhoea NOS (below serious, 11 patient) Constipation (below serious, 8 patients) Vomiting NOS (below serious, 5 patients) Dizziness (below serious, 9 patients) Pyrexia (below serious, 6 patients) Nasopharyngitis (below serious, 6 patients) Pharyngitis (below serious, 6 patients) Sinusitis NOS (below serious, 5 patients) Alanine aminotransferase increased (below serious, 5 patients) Cramp muscle (below serious, 5 patients) Insomnia (below serious, 7 patients) |
10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
Other AEs: Fatigue, General physical health deterioration... Other AEs: Fatigue (serious, 1 patient) Sources: General physical health deterioration (serious, 2 patients) Mucosal inflammation (serious, 1 patient) Pneumonia (serious, 3 patients) Anal abscess (serious, 1 patient) Bacteraemia (serious, 1 patient) Cellulitis (serious, 1 patient) Erysipelas (serious, 1 patient) Gastroenteritis (serious, 1 patient) Pneumonia legionella (serious, 1 patient) Pyelonephritis (serious, 1 patient) Septic shock (serious, 2 patients) Urinary tract infection (serious, 1 patient) Epistaxis (serious, 1 patient) Lung disorder (serious, 1 patient) Pulmonary embolism (serious, 2 patients) Acute myeloid leukaemia (serious, 8 patients) Bladder cancer (serious, 1 patient) Breast cancer (serious, 1 patient) Colon cancer (serious, 1 patient) Colorectal cancer (serious, 1 patient) Histiocytosis haematophagic (serious, 1 patient) Refractory anaemia with an excess of blasts (serious, 2 patients) Confusional state (serious, 1 patient) Delirium (serious, 1 patient) Altered mood (serious, 1 patient) Acute myocardial infarction (serious, 2 patients) Cardiac failure (serious, 1 patient) Myocardial infarction (serious, 1 patient) Tachyarrhythmia (serious, 1 patient) Abdominal pain (serious, 1 patient) Abdominal pain upper (serious, 1 patient) Colitis (serious, 1 patient) Constipation (serious, 1 patient) Diarrhoea (serious, 3 patients) Intestinal obstruction (serious, 1 patient) Femoral neck fracture (serious, 1 patient) Humerus fracture (serious, 1 patient) Spinal compression fracture (serious, 1 patient) Subdural haematoma (serious, 1 patient) Synovial rupture (serious, 1 patient) Hyperglycaemia (serious, 1 patient) Cerebral haemorrhage (serious, 1 patient) Cerebrovascular accident (serious, 1 patient) Coma (serious, 1 patient) Headache (serious, 1 patient) Colic renal (serious, 1 patient) Renal failure (serious, 1 patient) Stress urinary incontinence (serious, 1 patient) Deep vein thrombosis (serious, 4 patients) Arterial occlusive disease (serious, 1 patient) Hypotension (serious, 1 patient) Orthostatic hypotension (serious, 1 patient) Anaemia (serious, 1 patient) Autoimmune thrombocytopenia (serious, 1 patient) Bone marrow failure (serious, 1 patient) Febrile neutropenia (serious, 2 patients) Haemolysis (serious, 1 patient) Neutropenia (serious, 5 patients) Pancytopenia (serious, 1 patient) Splenomegaly (serious, 1 patient) Thrombocytopenia (serious, 3 patients) Arthritis (serious, 1 patient) Back pain (serious, 2 patients) Joint range of motion decreased (serious, 1 patient) Musculoskeletal pain (serious, 1 patient) Skin ulcer (serious, 1 patient) Urticaria (serious, 1 patient) Diarrhoea (below serious, 37 patients) Nausea (below serious, 21 patient) Constipation (below serious, 19 patients) Abdominal pain (below serious, 14 patients) Vomiting (below serious, 9 patients) Dry mouth (below serious, 5 patients) Abdominal pain upper (below serious, 8 patients) Dyspepsia (below serious, 5 patients) Flatulence (below serious, 1 patient) Fatigue (below serious, 17 patients) Oedema peripheral (below serious, 13 patients) Pyrexia (below serious, 16 patients) Influenza like illness (below serious, 5 patients) Oedema (below serious, 4 patients) Pain (below serious, 4 patients) Neutropenia (below serious, 57 patients) Leukopenia (below serious, 8 patients) Thrombocytopenia (below serious, 36 patients) Nasopharyngitis (below serious, 16 patients) Upper respiratory tract infection (below serious, 12 patients) Urinary tract infection (below serious, 12 patients) Bronchitis (below serious, 14 patients) Cystitis (below serious, 4 patients) Lower respiratory tract infection (below serious, 5 patients) Respiratory tract infection (below serious, 3 patients) Sinusitis (below serious, 6 patients) Gastroenteritis (below serious, 6 patients) Influenza (below serious, 5 patients) Pharyngitis (below serious, 4 patients) Rhinitis (below serious, 3 patients) Headache (below serious, 14 patients) Dizziness (below serious, 10 patients) Sciatica (below serious, 4 patients) Balance disorder (below serious, 4 patients) Peripheral sensory neuropathy (below serious, 1 patient) Muscle spasms (below serious, 15 patients) Back pain (below serious, 8 patients) Myalgia (below serious, 6 patients) Arthralgia (below serious, 5 patients) Pain in extremity (below serious, 10 patients) Musculoskeletal chest pain (below serious, 5 patients) Neck pain (below serious, 3 patients) Decreased appetite (below serious, 8 patients) Iron overload (below serious, 5 patients) Hypoalbuminaemia (below serious, 1 patient) Hypokalaemia (below serious, 3 patients) Hypomagnesaemia (below serious, 3 patients) Cough (below serious, 10 patients) Dyspnoea (below serious, 9 patients) Epistaxis (below serious, 4 patients) Dyspnoea exertional (below serious, 3 patients) Oropharyngeal pain (below serious, 6 patients) Pruritus (below serious, 20 patients) Dry skin (below serious, 10 patients) Rash (below serious, 12 patients) Alopecia (below serious, 4 patients) Hyperhidrosis (below serious, 4 patients) Petechiae (below serious, 4 patients) Insomnia (below serious, 9 patients) Anxiety (below serious, 5 patients) Contusion (below serious, 4 patients) Fall (below serious, 4 patients) Joint sprain (below serious, 1 patient) Wound (below serious, 4 patients) Alanine aminotransferase increased (below serious, 5 patients) Weight decreased (below serious, 5 patients) Haematoma (below serious, 6 patients) Phlebitis (below serious, 4 patients) Hypertension (below serious, 9 patients) Cataract (below serious, 5 patients) Conjunctivitis (below serious, 5 patients) Dysuria (below serious, 3 patients) Vertigo (below serious, 3 patients) Musculoskeletal pain (below serious, 11 patient) |
15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 4 Health Status: unhealthy Condition: Mantle Cell Lymphoma Population Size: 4 Sources: |
Other AEs: Squamous cell carcinoma, Herpes zoster... Other AEs: Squamous cell carcinoma (serious, 1 patient) Sources: Herpes zoster (below serious, 1 patient) Herpes zoster ophthalmic (below serious, 1 patient) Viral rash (below serious, 1 patient) Thrombocytopenia (below serious, 1 patient) Neutropenia (below serious, 1 patient) Constipation (below serious, 1 patient) Abdominal pain upper (below serious, 1 patient) Diarrhoea (below serious, 1 patient) Dry mouth (below serious, 1 patient) Flatulence (below serious, 1 patient) Stomatitis (below serious, 1 patient) Chills (below serious, 1 patient) Oedema peripheral (below serious, 1 patient) Dysgeusia (below serious, 1 patient) Peripheral sensory neuropathy (below serious, 1 patient) Eczema (below serious, 1 patient) Rash (below serious, 1 patient) Conjunctivitis (below serious, 1 patient) Muscle spasms (below serious, 1 patient) Neck pain (below serious, 1 patient) Basal cell carcinoma (below serious, 1 patient) Malignant melanoma (below serious, 1 patient) Libido decreased (below serious, 1 patient) Erectile dysfunction (below serious, 1 patient) |
25 mg 1 times / day steady, oral Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: |
unhealthy n = 22 Health Status: unhealthy Condition: Plasma Cell Dyscrasias Population Size: 22 Sources: |
Other AEs: Bleeding, Ischemic colitis... Other AEs: Bleeding (serious, 1 patient) Sources: Ischemic colitis (serious, 1 patient) |
5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
Other AEs: Pyrexia, Generalised oedema... Other AEs: Pyrexia (serious, 5 patients) Sources: Generalised oedema (serious, 1 patient) Non-cardiac chest pain (serious, 1 patient) Pneumonia (serious, 5 patients) Erysipelas (serious, 1 patient) Gastroenteritis (serious, 1 patient) Infection (serious, 1 patient) Lower respiratory tract infection (serious, 1 patient) Respiratory tract infection (serious, 1 patient) Staphylococcal sepsis (serious, 1 patient) Urinary tract infection (serious, 3 patients) Urosepsis (serious, 1 patient) Chronic obstructive pulmonary disease (serious, 1 patient) Hypoxia (serious, 1 patient) Lung disorder (serious, 1 patient) Aspiration pneumonia (serious, 1 patient) Pulmonary embolism (serious, 3 patients) Respiratory failure (serious, 1 patient) Acute myeloid leukaemia (serious, 8 patients) Leukaemia (serious, 1 patient) Lung cancer metastatic (serious, 1 patient) Myelodysplastic syndrome (serious, 1 patient) Refractory anaemia with an excess of blasts (serious, 1 patient) Anxiety disorder (serious, 1 patient) Altered mood (serious, 1 patient) Atrial fibrillation (serious, 2 patients) Cardiac failure (serious, 2 patients) Diarrhoea (serious, 1 patient) Intussusception (serious, 1 patient) Tooth disorder (serious, 1 patient) Fall (serious, 1 patient) Injury (serious, 1 patient) Transfusion reaction (serious, 1 patient) Diabetes mellitus inadequate control (serious, 1 patient) Hyperglycaemia (serious, 1 patient) Hypoglycaemia (serious, 1 patient) Headache (serious, 1 patient) Renal failure (serious, 1 patient) Urinary incontinence (serious, 1 patient) Phlebitis (serious, 1 patient) Venous thrombosis (serious, 1 patient) Anaemia (serious, 4 patients) Febrile neutropenia (serious, 2 patients) Neutropenia (serious, 5 patients) Pancytopenia (serious, 1 patient) Thrombocytopenia (serious, 6 patients) International normalised ratio increased (serious, 1 patient) Urine human chorionic gonadotropin abnormal (serious, 1 patient) Fibromyalgia (serious, 1 patient) Muscle spasms (serious, 1 patient) Myalgia (serious, 1 patient) Pyoderma gangrenosum (serious, 1 patient) Cytogenetic abnormality (serious, 1 patient) Diarrhoea (below serious, 32 patients) Nausea (below serious, 16 patients) Constipation (below serious, 18 patients) Abdominal pain (below serious, 7 patients) Vomiting (below serious, 8 patients) Dry mouth (below serious, 4 patients) Abdominal pain upper (below serious, 8 patients) Dyspepsia (below serious, 4 patients) Flatulence (below serious, 2 patients) Fatigue (below serious, 17 patients) Oedema peripheral (below serious, 15 patients) Pyrexia (below serious, 11 patient) Non-cardiac chest pain (below serious, 5 patients) Influenza like illness (below serious, 5 patients) Oedema (below serious, 3 patients) Pain (below serious, 1 patient) Neutropenia (below serious, 55 patients) Anaemia (below serious, 10 patients) Leukopenia (below serious, 12 patients) Thrombocytopenia (below serious, 38 patients) Nasopharyngitis (below serious, 15 patients) Upper respiratory tract infection (below serious, 11 patient) Urinary tract infection (below serious, 6 patients) Bronchitis (below serious, 7 patients) Cystitis (below serious, 2 patients) Lower respiratory tract infection (below serious, 2 patients) Respiratory tract infection (below serious, 9 patients) Gastroenteritis (below serious, 7 patients) Gastroenteritis viral (below serious, 4 patients) Influenza (below serious, 5 patients) Oral herpes (below serious, 6 patients) Pharyngitis (below serious, 3 patients) Rhinitis (below serious, 4 patients) Headache (below serious, 12 patients) Dizziness (below serious, 8 patients) Paraesthesia (below serious, 8 patients) Peripheral sensory neuropathy (below serious, 4 patients) Muscle spasms (below serious, 12 patients) Back pain (below serious, 12 patients) Myalgia (below serious, 4 patients) Arthralgia (below serious, 6 patients) Pain in extremity (below serious, 5 patients) Musculoskeletal chest pain (below serious, 1 patient) Neck pain (below serious, 3 patients) Decreased appetite (below serious, 8 patients) Iron overload (below serious, 4 patients) Hypoalbuminaemia (below serious, 4 patients) Hypokalaemia (below serious, 7 patients) Hypomagnesaemia (below serious, 3 patients) Cough (below serious, 12 patients) Dyspnoea (below serious, 12 patients) Epistaxis (below serious, 3 patients) Dyspnoea exertional (below serious, 4 patients) Oropharyngeal pain (below serious, 7 patients) Pruritus (below serious, 16 patients) Dry skin (below serious, 10 patients) Rash (below serious, 18 patients) Hyperhidrosis (below serious, 2 patients) Petechiae (below serious, 3 patients) Insomnia (below serious, 6 patients) Depression (below serious, 4 patients) Anxiety (below serious, 3 patients) Contusion (below serious, 3 patients) Fall (below serious, 2 patients) Wound (below serious, 2 patients) Alanine aminotransferase increased (below serious, 7 patients) Weight decreased (below serious, 6 patients) Haematoma (below serious, 6 patients) Hypertension (below serious, 7 patients) Cataract (below serious, 1 patient) Vertigo (below serious, 8 patients) Musculoskeletal pain (below serious, 5 patients) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Birth defects | serious | 10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
pregnant, adult Health Status: pregnant Age Group: adult Sex: F Sources: |
| Abdominal pain NOS | 0.5% Disc. AE |
10 mg 1 times / day steady, oral (starting) Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: Page: p. 101 |
unhealthy, adult n = 395 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 395 Sources: Page: p. 101 |
| Anemia hemolytic (NOS) | 0.5% Disc. AE |
10 mg 1 times / day steady, oral (starting) Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: Page: p. 101 |
unhealthy, adult n = 395 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 395 Sources: Page: p. 101 |
| Arthralgia | 0.5% Disc. AE |
10 mg 1 times / day steady, oral (starting) Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: Page: p. 101 |
unhealthy, adult n = 395 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 395 Sources: Page: p. 101 |
| Cough | 0.5% Disc. AE |
10 mg 1 times / day steady, oral (starting) Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: Page: p. 101 |
unhealthy, adult n = 395 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 395 Sources: Page: p. 101 |
| Face edema | 0.5% Disc. AE |
10 mg 1 times / day steady, oral (starting) Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: Page: p. 101 |
unhealthy, adult n = 395 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 395 Sources: Page: p. 101 |
| Pruritus | 0.5% Disc. AE |
10 mg 1 times / day steady, oral (starting) Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: Page: p. 101 |
unhealthy, adult n = 395 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 395 Sources: Page: p. 101 |
| Dyspnea | 0.8% Disc. AE |
10 mg 1 times / day steady, oral (starting) Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: Page: p. 101 |
unhealthy, adult n = 395 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 395 Sources: Page: p. 101 |
| Pyrexia | 0.8% Disc. AE |
10 mg 1 times / day steady, oral (starting) Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: Page: p. 101 |
unhealthy, adult n = 395 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 395 Sources: Page: p. 101 |
| Abdominal distension | 1% Disc. AE |
10 mg 1 times / day steady, oral (starting) Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: Page: p. 101 |
unhealthy, adult n = 395 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 395 Sources: Page: p. 101 |
| Anaemia NOS | 1% Disc. AE |
10 mg 1 times / day steady, oral (starting) Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: Page: p. 101 |
unhealthy, adult n = 395 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 395 Sources: Page: p. 101 |
| Fatigue | 1% Disc. AE |
10 mg 1 times / day steady, oral (starting) Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: Page: p. 101 |
unhealthy, adult n = 395 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 395 Sources: Page: p. 101 |
| Pneumonia NOS | 1% Disc. AE |
10 mg 1 times / day steady, oral (starting) Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: Page: p. 101 |
unhealthy, adult n = 395 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 395 Sources: Page: p. 101 |
| Diarrhea | 1.3% Disc. AE |
10 mg 1 times / day steady, oral (starting) Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: Page: p. 101 |
unhealthy, adult n = 395 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 395 Sources: Page: p. 101 |
| Nausea | 1.5% Disc. AE |
10 mg 1 times / day steady, oral (starting) Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: Page: p. 101 |
unhealthy, adult n = 395 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 395 Sources: Page: p. 101 |
| Rash | 2% Disc. AE |
10 mg 1 times / day steady, oral (starting) Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: Page: p. 101 |
unhealthy, adult n = 395 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 395 Sources: Page: p. 101 |
| Neutropenia | 3.5% Disc. AE |
10 mg 1 times / day steady, oral (starting) Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: Page: p. 101 |
unhealthy, adult n = 395 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 395 Sources: Page: p. 101 |
| Thrombocytopenia | 6.1% Disc. AE |
10 mg 1 times / day steady, oral (starting) Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: Page: p. 101 |
unhealthy, adult n = 395 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 395 Sources: Page: p. 101 |
| Neutropenia | 10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
|
| Pulmonary embolism | 10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
|
| Thrombocytopenia | 10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
|
| Thrombosis venous deep | 10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
|
| Diarrhoea NOS | below serious, 11 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 87 Health Status: unhealthy Condition: Complex Regional Pain Syndrome Population Size: 87 Sources: |
| Rash NOS | below serious, 24 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 87 Health Status: unhealthy Condition: Complex Regional Pain Syndrome Population Size: 87 Sources: |
| Alanine aminotransferase increased | below serious, 5 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 87 Health Status: unhealthy Condition: Complex Regional Pain Syndrome Population Size: 87 Sources: |
| Cramp muscle | below serious, 5 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 87 Health Status: unhealthy Condition: Complex Regional Pain Syndrome Population Size: 87 Sources: |
| Sinusitis NOS | below serious, 5 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 87 Health Status: unhealthy Condition: Complex Regional Pain Syndrome Population Size: 87 Sources: |
| Vomiting NOS | below serious, 5 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 87 Health Status: unhealthy Condition: Complex Regional Pain Syndrome Population Size: 87 Sources: |
| Dry skin | below serious, 6 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 87 Health Status: unhealthy Condition: Complex Regional Pain Syndrome Population Size: 87 Sources: |
| Nasopharyngitis | below serious, 6 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 87 Health Status: unhealthy Condition: Complex Regional Pain Syndrome Population Size: 87 Sources: |
| Pharyngitis | below serious, 6 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 87 Health Status: unhealthy Condition: Complex Regional Pain Syndrome Population Size: 87 Sources: |
| Pyrexia | below serious, 6 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 87 Health Status: unhealthy Condition: Complex Regional Pain Syndrome Population Size: 87 Sources: |
| Insomnia | below serious, 7 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 87 Health Status: unhealthy Condition: Complex Regional Pain Syndrome Population Size: 87 Sources: |
| Constipation | below serious, 8 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 87 Health Status: unhealthy Condition: Complex Regional Pain Syndrome Population Size: 87 Sources: |
| Pruritus | below serious, 8 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 87 Health Status: unhealthy Condition: Complex Regional Pain Syndrome Population Size: 87 Sources: |
| Dizziness | below serious, 9 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 87 Health Status: unhealthy Condition: Complex Regional Pain Syndrome Population Size: 87 Sources: |
| Abortion spontaneous NOS | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 87 Health Status: unhealthy Condition: Complex Regional Pain Syndrome Population Size: 87 Sources: |
| Angioneurotic edema | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 87 Health Status: unhealthy Condition: Complex Regional Pain Syndrome Population Size: 87 Sources: |
| Arthritis NOS | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 87 Health Status: unhealthy Condition: Complex Regional Pain Syndrome Population Size: 87 Sources: |
| Blood human chorionic gonadotropin positive | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 87 Health Status: unhealthy Condition: Complex Regional Pain Syndrome Population Size: 87 Sources: |
| Blood potassium decreased | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 87 Health Status: unhealthy Condition: Complex Regional Pain Syndrome Population Size: 87 Sources: |
| Foot fracture | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 87 Health Status: unhealthy Condition: Complex Regional Pain Syndrome Population Size: 87 Sources: |
| Pain NOS | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 87 Health Status: unhealthy Condition: Complex Regional Pain Syndrome Population Size: 87 Sources: |
| Pregnancy test false positive | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 87 Health Status: unhealthy Condition: Complex Regional Pain Syndrome Population Size: 87 Sources: |
| Sick sinus syndrome | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 87 Health Status: unhealthy Condition: Complex Regional Pain Syndrome Population Size: 87 Sources: |
| Thrombosis | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 87 Health Status: unhealthy Condition: Complex Regional Pain Syndrome Population Size: 87 Sources: |
| Joint sprain | serious, 2 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 87 Health Status: unhealthy Condition: Complex Regional Pain Syndrome Population Size: 87 Sources: |
| Pregnancy NOS | serious, 2 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 87 Health Status: unhealthy Condition: Complex Regional Pain Syndrome Population Size: 87 Sources: |
| Flatulence | below serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Hypoalbuminaemia | below serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Joint sprain | below serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Peripheral sensory neuropathy | below serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Cough | below serious, 10 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Dizziness | below serious, 10 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Dry skin | below serious, 10 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Pain in extremity | below serious, 10 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Musculoskeletal pain | below serious, 11 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Rash | below serious, 12 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Upper respiratory tract infection | below serious, 12 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Urinary tract infection | below serious, 12 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Oedema peripheral | below serious, 13 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Abdominal pain | below serious, 14 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Bronchitis | below serious, 14 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Headache | below serious, 14 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Muscle spasms | below serious, 15 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Nasopharyngitis | below serious, 16 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Pyrexia | below serious, 16 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Fatigue | below serious, 17 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Constipation | below serious, 19 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Pruritus | below serious, 20 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Nausea | below serious, 21 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Dyspnoea exertional | below serious, 3 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Dysuria | below serious, 3 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Hypokalaemia | below serious, 3 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Hypomagnesaemia | below serious, 3 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Neck pain | below serious, 3 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Respiratory tract infection | below serious, 3 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Rhinitis | below serious, 3 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Vertigo | below serious, 3 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Thrombocytopenia | below serious, 36 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Diarrhoea | below serious, 37 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Alopecia | below serious, 4 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Balance disorder | below serious, 4 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Contusion | below serious, 4 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Cystitis | below serious, 4 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Epistaxis | below serious, 4 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Fall | below serious, 4 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Hyperhidrosis | below serious, 4 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Oedema | below serious, 4 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Pain | below serious, 4 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Petechiae | below serious, 4 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Pharyngitis | below serious, 4 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Phlebitis | below serious, 4 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Sciatica | below serious, 4 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Wound | below serious, 4 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Alanine aminotransferase increased | below serious, 5 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Anxiety | below serious, 5 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Arthralgia | below serious, 5 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Cataract | below serious, 5 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Conjunctivitis | below serious, 5 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Dry mouth | below serious, 5 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Dyspepsia | below serious, 5 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Influenza like illness | below serious, 5 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Influenza | below serious, 5 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Iron overload | below serious, 5 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Lower respiratory tract infection | below serious, 5 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Musculoskeletal chest pain | below serious, 5 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Weight decreased | below serious, 5 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Neutropenia | below serious, 57 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Gastroenteritis | below serious, 6 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Haematoma | below serious, 6 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Myalgia | below serious, 6 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Oropharyngeal pain | below serious, 6 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Sinusitis | below serious, 6 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Abdominal pain upper | below serious, 8 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Back pain | below serious, 8 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Decreased appetite | below serious, 8 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Leukopenia | below serious, 8 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Dyspnoea | below serious, 9 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Hypertension | below serious, 9 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Insomnia | below serious, 9 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Vomiting | below serious, 9 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Abdominal pain upper | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Abdominal pain | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Altered mood | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Anaemia | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Anal abscess | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Arterial occlusive disease | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Arthritis | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Autoimmune thrombocytopenia | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Bacteraemia | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Bladder cancer | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Bone marrow failure | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Breast cancer | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Cardiac failure | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Cellulitis | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Cerebral haemorrhage | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Cerebrovascular accident | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Colic renal | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Colitis | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Colon cancer | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Colorectal cancer | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Coma | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Confusional state | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Constipation | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Delirium | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Epistaxis | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Erysipelas | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Fatigue | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Femoral neck fracture | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Gastroenteritis | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Haemolysis | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Headache | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Histiocytosis haematophagic | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Humerus fracture | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Hyperglycaemia | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Hypotension | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Intestinal obstruction | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Joint range of motion decreased | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Lung disorder | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Mucosal inflammation | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Musculoskeletal pain | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Myocardial infarction | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Orthostatic hypotension | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Pancytopenia | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Pneumonia legionella | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Pyelonephritis | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Renal failure | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Skin ulcer | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Spinal compression fracture | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Splenomegaly | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Stress urinary incontinence | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Subdural haematoma | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Synovial rupture | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Tachyarrhythmia | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Urinary tract infection | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Urticaria | serious, 1 patient | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Acute myocardial infarction | serious, 2 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Back pain | serious, 2 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Febrile neutropenia | serious, 2 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| General physical health deterioration | serious, 2 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Pulmonary embolism | serious, 2 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Refractory anaemia with an excess of blasts | serious, 2 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Septic shock | serious, 2 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Diarrhoea | serious, 3 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Pneumonia | serious, 3 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Thrombocytopenia | serious, 3 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Deep vein thrombosis | serious, 4 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Neutropenia | serious, 5 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Acute myeloid leukaemia | serious, 8 patients | 10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Abdominal pain upper | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 4 Health Status: unhealthy Condition: Mantle Cell Lymphoma Population Size: 4 Sources: |
| Basal cell carcinoma | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 4 Health Status: unhealthy Condition: Mantle Cell Lymphoma Population Size: 4 Sources: |
| Chills | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 4 Health Status: unhealthy Condition: Mantle Cell Lymphoma Population Size: 4 Sources: |
| Conjunctivitis | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 4 Health Status: unhealthy Condition: Mantle Cell Lymphoma Population Size: 4 Sources: |
| Constipation | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 4 Health Status: unhealthy Condition: Mantle Cell Lymphoma Population Size: 4 Sources: |
| Diarrhoea | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 4 Health Status: unhealthy Condition: Mantle Cell Lymphoma Population Size: 4 Sources: |
| Dry mouth | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 4 Health Status: unhealthy Condition: Mantle Cell Lymphoma Population Size: 4 Sources: |
| Dysgeusia | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 4 Health Status: unhealthy Condition: Mantle Cell Lymphoma Population Size: 4 Sources: |
| Eczema | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 4 Health Status: unhealthy Condition: Mantle Cell Lymphoma Population Size: 4 Sources: |
| Erectile dysfunction | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 4 Health Status: unhealthy Condition: Mantle Cell Lymphoma Population Size: 4 Sources: |
| Flatulence | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 4 Health Status: unhealthy Condition: Mantle Cell Lymphoma Population Size: 4 Sources: |
| Herpes zoster ophthalmic | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 4 Health Status: unhealthy Condition: Mantle Cell Lymphoma Population Size: 4 Sources: |
| Herpes zoster | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 4 Health Status: unhealthy Condition: Mantle Cell Lymphoma Population Size: 4 Sources: |
| Libido decreased | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 4 Health Status: unhealthy Condition: Mantle Cell Lymphoma Population Size: 4 Sources: |
| Malignant melanoma | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 4 Health Status: unhealthy Condition: Mantle Cell Lymphoma Population Size: 4 Sources: |
| Muscle spasms | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 4 Health Status: unhealthy Condition: Mantle Cell Lymphoma Population Size: 4 Sources: |
| Neck pain | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 4 Health Status: unhealthy Condition: Mantle Cell Lymphoma Population Size: 4 Sources: |
| Neutropenia | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 4 Health Status: unhealthy Condition: Mantle Cell Lymphoma Population Size: 4 Sources: |
| Oedema peripheral | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 4 Health Status: unhealthy Condition: Mantle Cell Lymphoma Population Size: 4 Sources: |
| Peripheral sensory neuropathy | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 4 Health Status: unhealthy Condition: Mantle Cell Lymphoma Population Size: 4 Sources: |
| Rash | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 4 Health Status: unhealthy Condition: Mantle Cell Lymphoma Population Size: 4 Sources: |
| Stomatitis | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 4 Health Status: unhealthy Condition: Mantle Cell Lymphoma Population Size: 4 Sources: |
| Thrombocytopenia | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 4 Health Status: unhealthy Condition: Mantle Cell Lymphoma Population Size: 4 Sources: |
| Viral rash | below serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 4 Health Status: unhealthy Condition: Mantle Cell Lymphoma Population Size: 4 Sources: |
| Squamous cell carcinoma | serious, 1 patient | 15 mg 1 times / day steady, oral Dose: 15 mg, 1 times / day Route: oral Route: steady Dose: 15 mg, 1 times / day Sources: |
unhealthy n = 4 Health Status: unhealthy Condition: Mantle Cell Lymphoma Population Size: 4 Sources: |
| Bleeding | serious, 1 patient | 25 mg 1 times / day steady, oral Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: |
unhealthy n = 22 Health Status: unhealthy Condition: Plasma Cell Dyscrasias Population Size: 22 Sources: |
| Ischemic colitis | serious, 1 patient | 25 mg 1 times / day steady, oral Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: |
unhealthy n = 22 Health Status: unhealthy Condition: Plasma Cell Dyscrasias Population Size: 22 Sources: |
| Cataract | below serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Musculoskeletal chest pain | below serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Pain | below serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Anaemia | below serious, 10 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Dry skin | below serious, 10 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Pyrexia | below serious, 11 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Upper respiratory tract infection | below serious, 11 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Back pain | below serious, 12 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Cough | below serious, 12 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Dyspnoea | below serious, 12 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Headache | below serious, 12 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Leukopenia | below serious, 12 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Muscle spasms | below serious, 12 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Nasopharyngitis | below serious, 15 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Oedema peripheral | below serious, 15 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Nausea | below serious, 16 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Pruritus | below serious, 16 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Fatigue | below serious, 17 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Constipation | below serious, 18 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Rash | below serious, 18 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Cystitis | below serious, 2 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Fall | below serious, 2 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Flatulence | below serious, 2 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Hyperhidrosis | below serious, 2 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Lower respiratory tract infection | below serious, 2 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Wound | below serious, 2 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Anxiety | below serious, 3 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Contusion | below serious, 3 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Epistaxis | below serious, 3 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Hypomagnesaemia | below serious, 3 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Neck pain | below serious, 3 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Oedema | below serious, 3 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Petechiae | below serious, 3 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Pharyngitis | below serious, 3 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Diarrhoea | below serious, 32 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Thrombocytopenia | below serious, 38 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Depression | below serious, 4 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Dry mouth | below serious, 4 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Dyspepsia | below serious, 4 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Dyspnoea exertional | below serious, 4 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Gastroenteritis viral | below serious, 4 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Hypoalbuminaemia | below serious, 4 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Iron overload | below serious, 4 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Myalgia | below serious, 4 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Peripheral sensory neuropathy | below serious, 4 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Rhinitis | below serious, 4 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Influenza like illness | below serious, 5 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Influenza | below serious, 5 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Musculoskeletal pain | below serious, 5 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Non-cardiac chest pain | below serious, 5 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Pain in extremity | below serious, 5 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Neutropenia | below serious, 55 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Arthralgia | below serious, 6 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Haematoma | below serious, 6 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Insomnia | below serious, 6 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Oral herpes | below serious, 6 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Urinary tract infection | below serious, 6 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Weight decreased | below serious, 6 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Abdominal pain | below serious, 7 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Alanine aminotransferase increased | below serious, 7 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Bronchitis | below serious, 7 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Gastroenteritis | below serious, 7 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Hypertension | below serious, 7 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Hypokalaemia | below serious, 7 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Oropharyngeal pain | below serious, 7 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Abdominal pain upper | below serious, 8 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Decreased appetite | below serious, 8 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Dizziness | below serious, 8 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Paraesthesia | below serious, 8 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Vertigo | below serious, 8 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Vomiting | below serious, 8 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Respiratory tract infection | below serious, 9 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Altered mood | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Anxiety disorder | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Aspiration pneumonia | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Chronic obstructive pulmonary disease | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Cytogenetic abnormality | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Diabetes mellitus inadequate control | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Diarrhoea | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Erysipelas | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Fall | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Fibromyalgia | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Gastroenteritis | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Generalised oedema | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Headache | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Hyperglycaemia | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Hypoglycaemia | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Hypoxia | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Infection | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Injury | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| International normalised ratio increased | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Intussusception | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Leukaemia | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Lower respiratory tract infection | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Lung cancer metastatic | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Lung disorder | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Muscle spasms | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Myalgia | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Myelodysplastic syndrome | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Non-cardiac chest pain | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Pancytopenia | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Phlebitis | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Pyoderma gangrenosum | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Refractory anaemia with an excess of blasts | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Renal failure | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Respiratory failure | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Respiratory tract infection | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Staphylococcal sepsis | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Tooth disorder | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Transfusion reaction | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Urinary incontinence | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Urine human chorionic gonadotropin abnormal | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Urosepsis | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Venous thrombosis | serious, 1 patient | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Atrial fibrillation | serious, 2 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Cardiac failure | serious, 2 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Febrile neutropenia | serious, 2 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Pulmonary embolism | serious, 3 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Urinary tract infection | serious, 3 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Anaemia | serious, 4 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Neutropenia | serious, 5 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Pneumonia | serious, 5 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Pyrexia | serious, 5 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Thrombocytopenia | serious, 6 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
| Acute myeloid leukaemia | serious, 8 patients | 5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 69 Health Status: unhealthy Condition: Myelodysplastic Syndrome Population Size: 69 Sources: |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| inconclusive | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | no (co-administration study) Comment: enzyme marker ethoxyresorufin O-dealkylase was used Page: 27.0 |
|||
| no | no (co-administration study) Comment: enzyme marker S-mephenytoin 4-hydroxylase Page: 27.0 |
|||
| no | no (co-administration study) Comment: enzyme marker tolbutamide methyl-hydroxylase Page: 27.0 |
|||
| no | no (co-administration study) Comment: enzyme marker bufuralol 1-hydroxylase Page: 27.0 |
|||
| no | no (co-administration study) Comment: enzyme marker lauric acid 11-hjydroxylase Page: 27.0 |
|||
| no | no (co-administration study) Comment: enzyme marker testosterone 6b-hydroxylase Page: 27.0 |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| inconclusive | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. | 2005 Dec 15 |
|
| Lenalidomide and thalidomide: mechanisms of action--similarities and differences. | 2005 Oct |
|
| Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. | 2006 Jul 1 |
|
| Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. | 2006 Jul 15 |
|
| Lenalidomide and venous thrombosis in multiple myeloma. | 2006 May 11 |
|
| Novel therapies in myeloma. | 2007 Nov |
|
| Development of rapid light-chain deposition disease in hepatic arteries with severe ischemic cholangitis in a multiple myeloma patient treated with melphalan, prednisone and lenalidomide. | 2009 Jan |
|
| Lenalidomide-induced acute liver failure. | 2009 Oct |
|
| Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. | 2009 Oct 1 |
|
| Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD). | 2010 Apr |
|
| Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. | 2010 Aug 5 |
|
| Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis. | 2010 Jun |
|
| Altered expression of signalling lymphocyte activation molecule (SLAM) family receptors CS1 (CD319) and 2B4 (CD244) in patients with systemic lupus erythematosus. | 2010 Jun |
|
| A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy. | 2010 Mar |
|
| Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma. | 2010 May |
|
| Stroke after treatment with bortezomib and dexamethasone in a Chinese patient with extramedullary relapse of multiple myeloma. | 2010 Nov |
|
| Activation of coagulation by lenalidomide-based regimens for the treatment of multiple myeloma. | 2013 |
|
| Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. | 2014 Aug 7 |
|
| "Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. | 2014 Jan |
|
| The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma. | 2014 Jan 16 |
|
| Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | 2015 May 18 |
Patents
Sample Use Guides
Multiple Myeloma:
REVLIMID ([lenalidomide capsules) 25 mg once daily on Days 1-21 of repeated 28-day cycles. The recommended dose of dexamethasone is 40 mg once daily on Days 1-4, 9-12, and 17-20 of each 28-day cycle for the first 4 cycles of therapy and then 40 mg once daily orally on Days 1-4 every 28 days. Treatment is continued or modified based upon clinical and laboratory findings
Myelodysplastic Syndromes:
The recommended starting dose of REVLIMID is 10 mg daily
Mantle Cell Lymphoma:
The recommended starting dose of REVLIMID is 25 mg/day orally on Days 1-21 of repeated 28-day cycles for relapsed or refractory mantle cell lymphoma
Route of Administration:
Oral
Lenalidomide enhances signaling via CAR19 receptor. To determine the costimulatory effect of lenalidomide, CAR19 T cells were stimulated with immobilized anti-CD3 antibody (clone MEM-57) or, with immobilized anti-CAR serum (polyclonal goat anti-mouse IgG FAB2) in the presence (10 MM, 1 MM) or absence of lenalidomide. The production of IFN in to culture supernatant was determined with ELISA after overnight co-incubation
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
XMU8E2M8RM
Created by
admin on Sat Dec 16 18:28:09 GMT 2023 , Edited by admin on Sat Dec 16 18:28:09 GMT 2023
|
PRIMARY | |||
|
100000174105
Created by
admin on Sat Dec 16 18:28:09 GMT 2023 , Edited by admin on Sat Dec 16 18:28:09 GMT 2023
|
PRIMARY | |||
|
165412089
Created by
admin on Sat Dec 16 18:28:09 GMT 2023 , Edited by admin on Sat Dec 16 18:28:09 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
